Lori Minasian, M.D., FACP

Dr. Lori Minasian, M.D., FACP, Deputy Director for the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI), is a board-certified medical oncologist with extensive experience in NCI clinical trials enterprise.

In her current role, Dr. Minasian leads the development of the new Cancer Screening Research Network (CSRN), a clinical trials network designed to evaluate emerging technologies for cancer screening. She has led the NCI Team in developing a framework for leveraging the CSRN to evaluate multi-cancer detection assays for cancer screening.

Previously, Dr. Minasian led NCI’s Community Clinical Oncology Program (CCOP) for more than 15 years and supported the development and conduct of numerous cancer prevention and control clinical trials.

Dr. Minasian has long supported the inclusion of patient reported outcomes in cancer clinical trials. She is one of the senior staff involved in conceptualization and development of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Event Reporting. This project emphasizes the importance of incorporating the patient’s perception into real-time reporting of adverse events for participants in clinical trials.

Dr. Minasian earned her M.D. degree from the George Washington University School of Medicine, completed her internal medicine residency at Case Western Reserve University, and finished her medicinal oncology training at Memorial Sloan Kettering Cancer Center.

Because the practice of oncology is rapidly evolving, Dr. Minasian continues to participate in the Women’s Malignancy Branch at the NIH Clinical Center, including teaching NCI oncology fellows.